Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Evan T, Hall"'
Publikováno v:
Cancers, Vol 13, Iss 14, p 3415 (2021)
Metastatic cancers resistant to immunotherapy require novel management strategies. DNA damage response (DDR) proteins, including ATR (ataxia telangiectasia and Rad3-related), ATM (ataxia telangiectasia mutated) and DNA-PK (DNA-dependent protein kinas
Externí odkaz:
https://doaj.org/article/448147aa39484ea292857f1c6dc2c413
Autor:
Evan T. Hall, John A. Thompson, Nathaniel F. Watson, Arthur Sillah, Joshua R. Veatch, Timothy A. Thornton, Scott S. Tykodi, Rachel C. Malen, Ulrike Peters, Amanda I. Phipps, Sylvia Lee, Jeannie Warner, Shailender Bhatia, Allison Silverman
Publikováno v:
Supportive Care in Cancer
Background: Sleep problems (SP) are common in cancer patients but have not been previously assessed in patients receiving immune checkpoint inhibitors (ICI).Methods: We collected questionnaire data on sleep apnea risk, insomnia and general sleep patt
Autor:
Andrew J, Portuguese, Jordan, Gauthier, Scott S, Tykodi, Evan T, Hall, Alexandre V, Hirayama, Cecilia C S, Yeung, Christopher D, Blosser
Publikováno v:
Bone marrow transplantation.
Post-transplant lymphoproliferative disorder (PTLD) is a leading cause of cancer death in solid organ transplant recipients (SOTRs). Relapsed or refractory (R/R) PTLD portends a high risk of death and effective management is not well established. CD1
Autor:
Xiaoyi Zheng, Fariborz Soroush, Jin Long, Evan T Hall, Puneeth K Adishesha, Sanchita Bhattacharya, Mohammad F Kiani, Vivek Bhalla
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0185250 (2017)
Diabetic nephropathy (DN) is the leading cause of kidney disease; however, there are no early biomarkers and no cure. Thus, there is a large unmet need to predict which individuals will develop nephropathy and to understand the molecular mechanisms t
Externí odkaz:
https://doaj.org/article/12f64a90f16e43c4ad6965dd57d96bd2
Autor:
Mollie F Qian, Nicolas J Betancourt, Alain Pineda, Nolan J Maloney, Kevin A Nguyen, Sunil A Reddy, Evan T Hall, Susan M Swetter, Lisa C Zaba
Publikováno v:
The oncologist.
Background Widespread implementation of immune checkpoint inhibitors (ICI) and targeted therapies for metastatic melanoma has led to a decline in melanoma-related mortality but increased healthcare costs. We aimed to determine how healthcare utilizat
Autor:
Evan E. Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K. Holt, Erin R. Dwyer, Joel Kramer, Kaylee Oliva, John L. Gore, George R. Schade, Daniel W. Lin, Scott S. Tykodi, Evan T. Hall, John A. Thompson, Anish Parikh, Yuanquan Yang, Katharine A. Collier, Abdul Miah, Sherry Mori-Vogt, Megan Hinkley, Amir Mortazavi, Paul Monk, Edmund Folefac, Steven K. Clinton, Sarah P. Psutka
Publikováno v:
Urologic oncology. 41(1)
Cytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma (mRCC) was called into question following the publication of the CARMENA trial. While previous retrospective studies have supported CN alongside targeted therapies, t
Autor:
Arthur Sillah, Shailender Bhatia, Nathaniel F. Watson, Jeannie Warner, Allison Silverman, Evan T. Hall, Scott S. Tykodi, Amanda I. Phipps, Ulrike Peters, Rachel C. Malen, John A. Thompson, Joshua R. Veatch, Sylvia Lee
Publikováno v:
Future Oncology. 17:363-369
Lifestyle factors could plausibly modulate the host immune system, the tumor microenvironment and, hence, immune checkpoint inhibitor (ICI) response. As such, these factors should be considered in ICI studies.
Autor:
Touran Fardeen, Ranak B. Trivedi, Lidia Schapira, Caroline Gray, Surbhi Singhal, Deepa Sridhar, Evan T. Hall, Sheila Lahijani
Publikováno v:
Supportive Care in Cancer. 29:2493-2500
Patients with cancer spend significant time receiving treatment and recovering from side effects. Little is known about how patients and their caregivers perceive time spent receiving cancer treatment and how this impacts health-related quality of li
Publikováno v:
American Society of Clinical Oncology Educational Book. :398-407
In this review, we summarize the immunology of nonmelanoma skin cancers (NMSCs) and the clinical data with immunotherapy in this heterogeneous group of cancers that include basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC), and Mer
Autor:
Sukhmani K. Padda, Touran Fardeen, George A. Fisher, Tyler Johnson, Gilbert Chu, Bianca Bruzzone, Brianna Velazquez, Gregory M. Heestand, Olga Generalova, Sigurdis Haraldsdottir, Sandy Srinivas, Kristen M. Cunanan, Mohana Roy, Robert W. Hsieh, Joel W. Neal, Heather A. Wakelee, Sumit A. Shah, Evan T. Hall, Anna Cabot, Kavitha Ramchandran, Alice C. Fan
Publikováno v:
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-11 (2021)
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-11 (2021)
Background Patient reported outcomes (PROs) have been associated with improved symptom management and quality of life in patients with cancer. However, the implementation of PROs in an academic clinical practice has not been thoroughly described. Her